Hong Kong Market Moves | Most innovative drug-related stocks rise as industry BD deals remain robust; policy support and the logic of commercial profitability realization remain intact

Most innovative drug-related stocks rose, with Kelun-Biotech (06990) up 8.62% to HK$428.4 and RemeGen (09995) up 8.11% to HK$75.3.

Zhitong Finance14:50

Hong Kong-listed innovative drug stocks rose collectively, with Hengrui Pharma and Wuxi XDC up over 5%.

Gelonghui, June 12 | Hong Kong-listed innovative drug stocks rallied collectively, with RemeGen and Kelun Biotech rising over 8%, InnoCare Pharma up more than 7%, Confo Therapeutics gaining over 6%, Hengrui Pharma, Lepu Biopharma, Akeso, Sino Biopharm, and Wuxi XDC all increasing by more than 5%, and Simcere Pharmaceutical and Innovent Bio climbing over 4%.

Gelonghui Finance14:34

Express News | Innovative drug stocks rebounded with volatility, with RemeGen surging over 10%.

Breakings13:39

Zhitong HK Stock Connect Holdings Ratio Anomaly Statistics | June 12

Zhitong HK Connect Holding Ratio Anomaly Statistics | June 11, 2026

Zhitong Finance08:36

J.P. Morgan Sticks to Their Buy Rating for RemeGen Co. Ltd. Class H (9995)

TipRanksJun 11 08:27 · Ratings

RemeGen Co. Ltd. Class H (9995) Gets a Buy From UBS

TipRanksJun 10 08:25 · Ratings